Mitochondrial dysfunction is increasingly recognized as a central factor in the pathogenesis of cardiovascular diseases (CVD), particularly in conditions such as heart failure, myocardial ischemia-reperfusion (I/R) injury, and cardiomyopathy. One of the most promising therapeutic peptides emerging from this field is SS-31, also known as elamipretide. Designed to selectively target mitochondria, SS-31 has demonstrated compelling cardioprotective effects in both preclinical and clinical models. This article explores the mechanisms by which SS-31 exerts its effects, its pharmacokinetic profile, and the potential clinical implications of its use in cardiovascular medicine.
Cardiac myocytes are among the most mitochondria-rich cells in the human body, relying heavily on oxidative phosphorylation (OXPHOS) for ATP production. Mitochondrial dysfunction in cardiomyocytes leads to:
Excessive reactive oxygen species (ROS) production
Disruption of ATP synthesis
Opening of the mitochondrial permeability transition pore (mPTP)
Release of pro-apoptotic factors
These processes play a central role in the development and progression of CVD. Hence, therapies that preserve mitochondrial function represent a novel and targeted approach to cardioprotection.
SS-31 is a cell-permeable, aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively localize to the inner mitochondrial membrane (IMM). Unlike other mitochondrial-targeted antioxidants (e.g., MitoQ), SS-31 does not rely on the mitochondrial membrane potential for uptake, allowing it to accumulate even in depolarized mitochondria.
Binds cardiolipin, a unique phospholipid of the IMM essential for mitochondrial structure and function.
Reduces mitochondrial ROS without acting as a classical antioxidant.
Preserves mitochondrial bioenergetics.
Prevents mitochondrial swelling and cytochrome c release.
1. Stabilization of Cardiolipin
Cardiolipin (CL) is critical for maintaining the curvature and structural integrity of the IMM and for anchoring respiratory chain supercomplexes. During stress (e.g., ischemia), CL is oxidized, leading to mitochondrial dysfunction and apoptosis. SS-31 binds to CL and:
Protects it from peroxidation.
Stabilizes cristae structure.
Promotes efficient electron transfer between complexes I–IV.
Key Insight: By preserving CL, SS-31 ensures the structural and functional integrity of the electron transport chain (ETC), reducing electron leak and ROS generation.
2. Reduction of Mitochondrial ROS and Oxidative Stress
SS-31 indirectly reduces ROS by maintaining proper ETC function, minimizing electron leakage. Studies also show it reduces levels of oxidized glutathione and lipid peroxidation products, preserving redox homeostasis.
3. Preservation of Mitochondrial Bioenergetics
In various models, SS-31 improves:
ATP synthesis
Mitochondrial membrane potential (Δψm)
Oxygen consumption rate (OCR)
These improvements are essential during I/R injury, where mitochondrial dysfunction sharply reduces energy production and leads to cell death.
4. Inhibition of mPTP Opening
The mitochondrial permeability transition pore (mPTP) opens in response to elevated ROS and calcium, triggering necrosis and apoptosis. SS-31 delays mPTP opening, particularly during reperfusion after ischemia.
Myocardial Ischemia-Reperfusion Injury
Multiple rodent studies have demonstrated that SS-31:
Reduces infarct size.
Improves cardiac contractility post-injury.
Preserves mitochondrial morphology and function.
In a landmark study by Szeto et al. (2008), SS-31 administered during reperfusion significantly reduced infarct size and preserved left ventricular (LV) function in rats.
Heart Failure Models
In murine models of pressure-overload and diabetic cardiomyopathy, SS-31:
Preserved LV ejection fraction.
Prevented adverse cardiac remodeling.
Reduced myocardial fibrosis.
Aging-Related Cardiomyopathy
In aged mice, SS-31 reversed age-related decline in diastolic function, improved exercise capacity, and enhanced mitochondrial respiration in cardiac tissue (Chiao et al., 2020).
Phase I and II Clinical Trials
Early-phase trials have demonstrated SS-31’s safety and tolerability in humans. In a Phase IIa trial (EMBRACE-STEMI), SS-31 (elamipretide) was tested in patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Although the primary endpoint (reduction in infarct size) was not met, secondary endpoints showed trends toward improved LV function and mitochondrial efficiency.
Heart Failure with Reduced Ejection Fraction (HFrEF)
In the PROGRESS-HF trial (NCT03992095), elamipretide was evaluated in HFrEF patients. While results are pending publication, early data suggest improved cardiac mitochondrial function and exercise tolerance.
1. Perioperative Cardioprotection
SS-31 could be used adjunctively during cardiac surgeries (e.g., CABG or valve replacement) to reduce perioperative myocardial injury, particularly in high-risk patients.
2. Mitochondrial Myopathies with Cardiac Involvement
Patients with primary mitochondrial diseases often develop cardiomyopathies. SS-31 shows potential in addressing the underlying mitochondrial deficits in these patients.
3. Aging and Heart Failure with Preserved Ejection Fraction (HFpEF)
HFpEF is closely associated with aging and metabolic dysfunction. Given SS-31’s effects in aging models, it may emerge as a therapy for this currently untreatable condition.
While SS-31 presents a compelling case for clinical application, certain limitations remain:
Clinical efficacy in large-scale trials remains to be confirmed.
Long-term safety and optimal dosing regimens are under investigation.
Its effects may vary based on the etiology of mitochondrial dysfunction (e.g., genetic vs. acquired).
SS-31 represents a novel, mitochondria-targeted therapeutic peptide with potent cardioprotective properties. By stabilizing cardiolipin, enhancing mitochondrial bioenergetics, and reducing oxidative stress, SS-31 addresses a root cause of cardiac dysfunction—mitochondrial impairment. While clinical translation is still ongoing, its promise as a treatment for heart failure, ischemic injury, and age-related cardiac decline positions it as a potential game-changer in cardiovascular medicine.
Szeto HH. “Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.” Annals of the New York Academy of Sciences. 2008;1147:112–121. https://doi.org/10.1196/annals.1427.015
Birk AV, Liu S, Soong Y, et al. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” J Am Soc Nephrol. 2013;24(8):1250–1261. https://doi.org/10.1681/ASN.2012121153
Chiao YA, Kolwicz SC Jr, Basisty N, et al. “Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice.” J Gerontol A Biol Sci Med Sci. 2020;75(2):260–269. https://doi.org/10.1093/gerona/glz049
Daubert MA, Yow E, Dunn G, et al. “Novel Mitochondria-Targeting Peptide in Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled Trial.” Circ Heart Fail. 2017;10:e004389. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004389
Brown DA, Perry JB, Allen ME, et al. “Targeting mitochondrial oxidative stress in heart failure with mitochondria-targeted antioxidants.” Circ Res. 2017;121(2):119–140. https://doi.org/10.1161/CIRCRESAHA.116.309326
Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders worldwide, characterized by progressive cognitive decline and memory impairment. Despite decades of research, therapeutic
Aging is a multifaceted biological process characterized by a progressive decline in physiological function and increased vulnerability to chronic diseases. At the cellular level, one
Aging is an intricate biological process characterized by the gradual decline in cellular and systemic functions, ultimately leading to increased susceptibility to diseases and mortality.
Mitochondrial-derived peptides (MDPs) have recently attracted significant interest for their multifaceted roles in cellular homeostasis, metabolism, and aging. Among these, MOTS-c (Mitochondrial Open Reading Frame
Copper peptides have long captured the attention of dermatologists and cosmetic chemists for their remarkable regenerative properties. Among them, GHK-Cu (glycyl-L-histidyl-L-lysine–copper) has emerged as a
